$LEGN has been mentioned 20 times over the past 12 months by 4 distinct FinTwit voices, with the first mention appearing on July 17, 2025. @jacobplieth has been the most active voice discussing Legend Biotech, accounting for 17 of the 20 mentions, followed by @cobraalerts with 5 mentions. @adamfeuerstein and @jonerlichman each contributed 1 mention. The most recent discussion occurred on June 15, 2026, when @jacobplieth noted the emergence of a fourth in vivo CAR-T candidate, LVIVO-TaVec122.

Discussions among these voices have primarily focused on Legend Biotech's clinical pipeline developments within the biotech sector. Recent commentary centered on data presentations at EHA2026, where @jacobplieth reported on the CD19 x CD20 CAR-T program LB2501, noting 0% overall response rate at dose level 1 but 100% ORR with 83% complete response rate at dose level 2. @jacobplieth also documented analyst perspectives from Evercore regarding the clinical findings and dosing clarity.